Quantcast

BioMS Medical to present at Alberta Economic Forum in Geneva

April 29, 2009

Toronto Stock Exchange Symbol: MS

EDMONTON, April 29 /PRNewswire-FirstCall/ – BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at a session entitled “Leveraging on energy wealth: the development of a world class technology sector” as part of the Alberta Economic Forum in Geneva in Switzerland.

    WHEN:     Monday May 4th at 10:05am (Local time)

    WHERE:    Grand Hotel Kempinski, Geneva, Switzerland

    About Alberta Economic Forum
    ----------------------------

The Alberta Economic Forum will profile direct and financial investment opportunities while also addressing the environmental, economical and technological issues critical to the long term success of investment in Alberta. With an anticipated 300 attendees, participants of the forum will include investment bankers, portfolio managers, independent wealth managers, private investors, financial analysts, and portfolio managers from both Europe and Canada, in addition to senior managers of the infrastructure sector and government. For more information visit http://www.albertaeconomicforum.com/

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical’s lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com

This press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMS Medical Corp.


Source: newswire



comments powered by Disqus